ScholarLens Back to search
2016•The Lancet OncologyRequires access

Benefits of pazopanib over sunitinib for renal cell carcinoma

Michael C. Granovetter

Open publisher page 6 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Pazopanib, Sunitinib, Renal cell carcinoma, Medicine, Oncology, Internal medicine, Toxicity, Angiogenesis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Benefits of pazopanib over sunitinib for renal cell carcinoma — Research Paper | ScholarLens